Title : Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date.

Pub. Date : 2018

PMID : 30147333






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Several agents, including idelalisib, copanlisib and duvelisib, not only inhibit the PI3K pathway, but also have effects on associated mechanisms including the ATK and mTOR pathways. duvelisib mechanistic target of rapamycin kinase Homo sapiens